Gerstberger, Thomas
Boehringer Ingelheim (Austria)
6 papers on CoChatORCID 0000-0002-6837-1401
Most cited papers
- Verified
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology
Protein Degradation and InhibitorsChromatin Remodeling and Cancer
Cited by 562
- Verified
Drugging an undruggable pocket on KRAS
Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 449
- Verified
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 444
- Verified
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports
Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment
Cited by 207
- Verified
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS G12C Inhibitor
Bröker, J., Waterson, A. G., Smethurst, C., Kessler, D., Böttcher, J., Mayer, M., Gmaschitz, G., Phan, J., Little, A., Abbott, J. R., et al. (2022) · Journal of Medicinal Chemistry
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 96
- Verified
Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan
Gerlach, D., Gmachl, M., Ramharter, J., Teh, J., Fu, S.-C., Trapani, F., Kessler, D., Rumpel, K., Botesteanu, D.-A., Ettmayer, P., et al. (2020) · Cancer Research
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 53
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free